Slide 1: Glaukos Corporation Second Quarter 2026 in Review
GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performan
Slide 2: Glaukos: Transforming Vision. We'll Go First
GLAUKOS TRANSFORMING VISION. WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 3: Second Quarter 2026 Financial Results Summary
Business Description Disease Categories Revenue (Growth) Gross Margin (Non-GAAP) Cash & Cash Equivalents, Short-Term Investments, and Restricted Cash FY2026 Sales Guidance SECOND QUARTER 2026 FINANCIAL RESULTS SUMMARY Ophthalmic pharmaceutical and medical technology company focused on developing and
Slide 4: Revenue Performance & Commercial Overview
Revenue Performance & Commercial Overview Global Consolidated Revenue Performance Glaukos reported record second quarter net revenues of $185.6 million that were up 50% on a reported basis, or 49% on a constant currency basis, versus 2Q 2025. Our second quarter record results reflect a sustained gro
Slide 5: Franchise Revenue Performance
Franchise Revenue Performance
Slide 6: 2Q 2026 Revenue Mix
2Q 2026 Revenue Mix Corneal Health $30.4M U.S. Glaucoma $118.5M International Glaucoma $36.6M
Slide 7: U.S. Glaucoma
U.S. Glaucoma Our record second quarter U.S. Glaucoma net revenues were approximately $118.5 million, representing year-over-year growth of 64% versus 2Q 2025 driven by growing contributions from iDose TR , which generated sales of approximately $74 million in the second quarter. During the second q
Slide 8: Additional Commercial Updates & Commentary
Additional Commercial Updates & Commentary We have had several additional positive commercial updates worth highlighting here: Advanced commercial launch activities in the U.S. for iDose TR o Growing number of trained surgeons and accounts o Increasing utilization by the installed active surgeon b
Slide 9: CMS's Proposed Rules for Calendar Year 2027
CMS’s Proposed Rules for Calendar Year 2027 o Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Facility Fee Schedules: Proposed to maintain the 2026 APC assignments and largely maintain facility fee rates associated with our procedures across both the hosp
Slide 10: 2026 Revenue Guidance Raised to Reflect Strong Momentum
2026 Revenue Guidance Raised to Reflect Strong Momentum Glaukos now expects full-year 2026 global consolidated net sales of $680 - $700 million, up from its previous guidance of $620 - $635 million. This guidance attempts to take into consideration: Potential growing contributions from iDose TR as
Slide 11: Research & Development / Pipeline Overview
Research & Development / Pipeline Overview Pipeline Summary Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows: iStent® micro-scale surgical devices iDose® sustained-release procedural p
Slide 12: Open-Angle Glaucoma
Open-Angle Glaucoma -— Ocular Hypertension and _Keratoconus el; ier Blepharitis elid Delive Myopia——_—!
Slide 13: Key R&D and Pipeline Updates
Key R&D and Pipeline Updates We are continuing to invest in and advance our fulsome pipeline of core novel platforms, supported by more than $900 million investment into R&D since 2018 alone. Recent updates in our pipeline include:
Slide 14: Glaukos
GLAUKOS
Slide 15: Product / Pipeline Chart
Product / Pipeline Chart
Slide 16: Product Patient Status
PRODUCT PATIENT TATUS FDA Approved (2012, 2018, 2020) Mild-to-Moderate Glaucoma with Cataract Glaucoma (failed on prior therapy) FDA Cleared (2022) Glaucoma (label expansion) Active PMA Study / EU MDR Cert (2025) need Rfrecory Gano a Ocular Hypertension - Glaucoma FDA Approved (2023) Ocular Hyperten
Slide 17: Other Financial Performance Overview
Other Financial Performance Overview As a reminder, we discuss our financial performance on a non-GAAP basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Information section c
Slide 18: Other Important Updates
Other Important Updates Given the ongoing conversations around tariff and broader geopolitical volatility, we wanted to reiterate that we manufacture and source our products primarily within the U.S., and as such, expect minimal direct exposure to the most recently implemented tariff-related polic
Slide 19: Glaukos
GLAUKOS
Slide 20: Additional Information
Additional Information
Slide 21: Forward-Looking Statements
Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticip
Slide 22: Statement Regarding Use of Non-GAAP Financial Measures
We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. Statement Regarding Use of Non-GAAP Financial Measures To supplement the cons
Slide 23: Consolidated Statements of Operations
Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 Net sales $ 185,610 $ 124,120 $ 336,181 $ 230,784 Cost of sales 34,016 26,896 67,355 51,212 Gross profit 151,594 97,224 268,826 179,572 Operating expenses: Selling, general and administrative 116,060 83,375 209,003 154,048 Res
Slide 24: Consolidated Balance Sheets
June 30, December 31, 2026 2025 (unaudited) Assets Current assets: Cash and cash equivalents $ 114,485 $ 90,813 Short-term investments 171,741 187,947 Accounts receivable, net 138,900 108,608 Inventory 59,306 63,564 Prepaid expenses and other current assets 31,346 24,052 Total current assets 515,778
Slide 25: Primary GAAP to Non-GAAP Reconciliations Q2
Q2 2026 Q2 2025 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Cost of sales $ 34,016 (5,227 ) (a)(b) 28,742 $ 26,896 (5,764 ) (a)(b) $ 21,132 Gross Margin 81.7 % 2.8 % 84.5 % 78.3 % 4.7 % 83.0 % Operating expenses: Selling, general and administrative $ 116,060 $ (4,404 ) (c)(d)(e) $ 111,656 $
Slide 26: Primary GAAP to Non-GAAP Reconciliations Year-to-Date
Year-to-Date Q2 2026 Year-to-Date Q2 2025 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Cost of sales $ 67,355 $ (13,949 ) (a)(b) $ 53,406 $ 51,212 $ (11,287 ) (a)(b) $ 39,925 Gross Margin 80.0 % 4.1 % 84.1 % 77.8 % 4.9 % 82.7 % Operating expenses: Selling, general and administrative $ 209,003
Slide 27: Additional GAAP to Non-GAAP Reconciliations
Reported Sales vs. Prior Periods (in thousands) Year-over-Year Percent Change Quarter-over-Quarter Percent Change 1Q 2026 1Q 2025 4Q 2025 Reported Operations (1) Currency (2) Reported Operations (1) Currency (2) International Glaucoma $ 36,631 $ 31,251 $ 35,808 17.2 % 16.4 % 0.8 % 2.3 % 2.6 % (0.3 %